Replies to post #22363 on Intellipharmaceutics International Inc. (IPCI)

[Despicable_Z]

So good to see you back here WeeZuhl. As history has taught us, whenever you stop in...we can expect a drastic rise in share price and huge catalysts to be released shortly thereafter.

Welcome back! (hope you have bought up your shares :).

[numbersarefun]

WeeZuhl, Oxycontin marketing exclusivity for new patient population. You are incorrect in thinking Oxycontin has full marketing exclusivity until August 2018. It is only marketing exclusivity for the new patient population. If you search, maybe you can figure out what that new patient population is for Oxycontin.

Are you long ELTP and short IPCI? Anyway, I hope you did not short IPCI on your faulty research. And if you did, maybe you are making a mistake. Answer to question #4 is YES, Oxycontin has a type of marketing exclusivity, but it does not matter. Answer to #5 is Rexista might get Priority Review. Answer to #6 is PDUFA from 6 months from submission date is earliest Rexista can get approved. #5 and #6 are not "yes" or "no" questions, so how come your hint says they are the same answer?

WeeZuhl wrote:
"
4. Does the RLD have marketing exclusivity? If so, when does it expire?

5. Why does Rexista NOT get a Priority Review when all other ADF NDAs have?

6. What is the earliest date that Rexista could receive Full Approval from FDA?

(Hint: The Answer to #4, #5, and #6 is the same.)
"